Примери за използване на Given a marketing authorisation на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
They recommended that ProQuad be given a marketing authorisation.
The CVMP concluded that the benefits of Comfortis outweigh the risks when used for the approved indications andrecommended that Comfortis be given a marketing authorisation.
They recommended that Ibraxion should be given a marketing authorisation.
The Committee for Medicinal Products for Veterinary Use(CVMP) concluded that the benefits of Onsior exceed the risks for the treatment of dogs and cats in the approved indications andrecommended that Onsior should be given a marketing authorisation.
The Committee recommended that Recocam be given a marketing authorisation.
Хората също превеждат
The Committee for Medicinal Products for Veterinary Use(CVMP) concluded that the benefits of Convenia exceed the risks for the treatment of dogs and cats with certain specified skin, soft tissue and urinary tract infections andrecommended that Convenia should be given a marketing authorisation.
CVMP recommended that Quadrisol should be given a marketing authorisation.
The CVMP concluded that the benefits of Zolvix exceed the risks for the approved indications andrecommended that Zolvix be given a marketing authorisation.
The CVMP recommended that Netvax should be given a marketing authorisation.
Coli F5(K99) adhesin during the first days of life as a supplement to colostrum from the dam, andrecommended that Locatim be given a marketing authorisation.
The Committee recommended that DEXDOMITOR be given a marketing authorisation.
The CVMP concluded that the benefits of Suvaxyn CSF Marker exceed the risks for the approved indication andrecommended that Suvaxyn CSF Marker be given a marketing authorisation.
The Committee recommended that Econor should be given a marketing authorisation.
The Committee for Medicinal Products for Veterinary Use(CVMP) concluded that the benefits of Cardalis exceed the risks andrecommended that be given a marketing authorisation.
The Committee recommended that ProMeris Duo be given a marketing authorisation.
The Committee for Medicinal Products for Veterinary Use(CVMP) concluded that the benefits of Nobivac L4 exceed the risks andrecommended that it be given a marketing authorisation.
They recommended that Virbagen Omega should be given a marketing authorisation.
The CVMP concluded that the benefits of Coliprotec F4 exceed the risks for the approved indication andrecommended that Coliprotec F4 be given a marketing authorisation.
Indications and recommended that Comfortis be given a marketing authorisation.
The CVMP concluded that the benefits of ProZinc exceed the risks for the approved indication andrecommended that ProZinc be given a marketing authorisation.
The Committee therefore recommended that Naxcel should be given a marketing authorisation.
The Committee for Medicinal Products for Veterinary Use(CVMP) concluded that the benefits of Equip WNV outweigh the risks for the approved indication andrecommended that Equip WNV be given a marketing authorisation.
The Committee recommended that Nobivac Myxo-RHD be given a marketing authorisation.
The Committee for Medicinal Products for Veterinary Use(CVMP) concluded that the benefits of Porcilis ColiClos exceed the risks andrecommended that Porcilis ColiClos be given a marketing authorisation.
They recommended that Eurican Herpes 205 should be given a marketing authorisation.
The CVMP concluded that the benefits of Suvaxyn CSF Marker exceed the risks for the approved indication andrecommended that Suvaxyn CSF Marker be given a marketing authorisation.
They recommended that Fevaxyn Pentofel should be given a marketing authorisation.
The Committee for Medicinal Products for Veterinary Use(CVMP) concluded that the benefits of Bovela exceed the risks for the approved indication andrecommended that Bovela be given a marketing authorisation.
The Committee recommended that Equilis Prequenza Te should be given a marketing authorisation.
The Committee for Medicinal Products for Veterinary Use(CVMP) concluded that the benefits of Ypozane exceed its risks for the treatment of benign prostatic hypertrophy(BPH) in male dogs andrecommended that Ypozane be given a marketing authorisation.